10,503 results match your criteria Psoriatic Arthritis


Mortality in psoriatic arthritis: Risk, causes of death, predictors for death.

Semin Arthritis Rheum 2020 May 23;50(4):571-575. Epub 2020 May 23.

Centre for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON Canada; Institute of Medical Science, University of Toronto, Toronto, ON Canada. Electronic address:

Background/objectives: Mortality studies in psoriatic arthritis (PsA) have provided inconsistent results. This study aimed to: 1) Estimate trends in mortality rates among PsA patients over calendar time; 2) Evaluate cause-specific mortality rates in patients with PsA compared to the general population; 3) Identify predictors for mortality in PsA.

Methods: The study was carried out at the University of Toronto Psoriatic Arthritis Clinic where patients are followed prospectively according to a standard protocol at 6- to 12- month intervals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2020.04.001DOI Listing

Transient Osteoporosis of the Hip Mimicking Flare of Psoriatic Arthritis.

J Clin Rheumatol 2020 Jun;26(4):e79

From the Rheumatology Department, 417 "NIMTS", Army Share Fund Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000867DOI Listing

Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.

Clin Exp Rheumatol 2020 May 11. Epub 2020 May 11.

University of California, San Diego (UCSD) School of Medicine, Division of Rheumatology, Allergy, and Immunology, San Diego, CA, USA.

Objectives: To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically important difference (MCID) for work productivity loss and activity impairment domains of Work Productivity and Activity Impairment Specific Health Problem (WPAI-SHP) questionnaire.

Methods: In the SPIRIT-P1 study, comprising a 24-week double-blind treatment period, biologic-naive patients with active psoriatic arthritis (PsA) were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) (starting dose of 160 mg), adalimumab 40 mg every 2 weeks (ADAQ2W), or placebo. SPIRIT-P2 enrolled tumour necrosis factor inhibitor (TNFi)-experienced patients who were randomised to receive IXEQ4W, IXEQ2W or placebo for 24 weeks of double-blind treatment. Read More

View Article

Download full-text PDF

Source

Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients.

Clin Exp Rheumatol 2020 May 20. Epub 2020 May 20.

Clinica Medica 3, Department of Medicine DIMED, University of Padova; and Dipartimento di Medicina, Ospedaledi Mirano, Venezia, Italy.

Objectives: Our aim was to evaluate subclinical atherosclerosis progression during 5 years of anti-tumour necrosis factor (TNF)-α treatment in psoriatic arthritis (PsA) patients.

Methods: Thirty-two consecutive PsA patients starting TNF-α inhibitors were enrolled and evaluated at baseline (T0), 2 years (FU1) and 5 years (FU2) of treatment. Arterial structural properties were evaluated by B-mode ultrasound of mean carotid intima-media thickness (mean-IMT) and maximum IMT (M-MAX) in each segment (common, bulb, internal), bilaterally. Read More

View Article

Download full-text PDF

Source

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Rheumatology (Oxford) 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Mount Sinai Hospital, New York, NY, USA.

Objectives: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA.

Methods: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5 years' exposure are reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa189DOI Listing

Biocompatible nanovesicular drug delivery systems with targeting potential for autoimmune diseases.

Curr Pharm Des 2020 May 23. Epub 2020 May 23.

Delhi Pharmaceutical Sciences and Research University, New Delhi. India.

Autoimmune diseases are collectively addressed as chronic conditions initiated by loss of one's immunological tolerance, where body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer's, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612826666200523174108DOI Listing

Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines.

Authors:
Stanford Shoor

Infect Dis Clin North Am 2020 Jun;34(2):179-189

Stanford University, 1000 Welch Road Suite 203, Palo Alto, CA 94304, USA. Electronic address:

Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis and to prevent rejection of renal transplants. Inhibitors of the intereukin (IL-17) cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis and anti- IL-23 drugs for psoriasis. Serious infections occur in 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2020.02.001DOI Listing

Impact of Persistence with Tumor Necrosis Factor Inhibitors on Healthcare Resource Utilization and Costs in Chronic Inflammatory Joint Diseases.

Br J Clin Pharmacol 2020 May 22. Epub 2020 May 22.

Sorbonne Université, GRC 08, Institut Pierre Louis d'Epidémiologie et Santé Publique, AP-HP, Service de rhumatologie, Hôpital Pitié-Salpêtrière, F 75013, Paris, France.

Aim: To assess persistence with subcutaneous (SC) Tumor Necrosis Factor (TNF) inhibitors as well as the impact of persistence on healthcare resource utilization (HCRU) and costs in patients with chronic inflammatory joint diseases.

Methods: In this cohort study using population-based French claims data (from 2011 to 2014), we measured persistence with SC TNF inhibitors within 12 months (M0-12) following treatment initiation in treatment-naïve and treatment-experienced users (divided into 3 cohorts: rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]). Persistent patients were propensity score matched to non-persistent patients at M12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14387DOI Listing

Growth factors: Do they play a role in entheseal involvement in psoriatic arthritis and undifferentiated spondyloarthritis patients?

Reumatol Clin 2020 May 18. Epub 2020 May 18.

Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia, Ospedali Riuniti Foggia, Viale Pinto 1, 71121 Foggia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2020.01.002DOI Listing

Head-to-Head trials in inflammatory arthritis.

Joint Bone Spine 2020 May 10. Epub 2020 May 10.

Rheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2020.04.015DOI Listing

Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice.

Saudi Pharm J 2020 May 2;28(5):615-620. Epub 2020 Apr 2.

Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakakah-72341, Saudi Arabia.

Objective: Researchers have confirmed that chronic administration of drugs at high doses causes genotoxicity which serve as first step in development of cancers. Apremilast, a phosphodiesterase-4 inhibitor is Food and Drug Administration (FDA) approved drug for Psoriatic Arthritis. The present study designed to conduct genotoxicity testing using the genotoxic study which give simple, sensitive, economical and fast tools for the assessment of damage of genetic material. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsps.2020.03.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229325PMC
May 2020
1.000 Impact Factor

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

Ann Rheum Dis 2020 Jun;79(6):700-712

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Wien, Austria.

Objective: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA).

Methods: According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217159DOI Listing

EULAR PsA management recommendations 2019: can the recommendations be improved?

Ann Rheum Dis 2020 Jun;79(6):680-682

Medicine, University of Texas Southwestern, Dallas, TX 75390, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217236DOI Listing

How Variable Is the Volar Subcutaneous Tissue of the Digits on B-Mode and Color Doppler Ultrasound in Non-Psoriatic Individuals and Could It Be Included in a Dactylitis Score?

Ultraschall Med 2020 May 20. Epub 2020 May 20.

Department of Rheumatology, Joint and Bone Research Unit, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.

Background:  Digital subcutaneous tissue (SCT) changes are involved in dactylitis, a hallmark feature of psoriatic arthritis (PsA). There are no studies on the ultrasound (US) characteristics of the digital SCT in the general population.

Objectives:  To investigate the variability in US-measured thickness (TH) and color Doppler (CD)-detected blood flow of the SCT of the volar aspects of the fingers in a non-psoriatic population and to investigate the impact of the scanning method and demographics and clinical features on these measurements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1168-6636DOI Listing

Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.

Ann Rheum Dis 2020 May 19. Epub 2020 May 19.

Academic Rheumatology Centre, Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino, MFRU, Turin, Italy

Objectives: Dactylitis is one of the most typical features of psoriatic arthritis (PsA), with a high lifetime prevalence and inclusion in PsA clinical indices. Musculoskeletal ultrasonography (Msk-US) can readily detect inflammatory involvement of finger anatomical structures particular to dactylitis and monitor therapeutic effects. In this study, we aim to identify the characteristic lesions in PsA dactylitis of the hands, assess the reliability of Msk-US in scoring those lesions and develop a DACTylitis glObal Sonographic (DACTOS) score. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217191DOI Listing

Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice.

Sci Rep 2020 May 19;10(1):8259. Epub 2020 May 19.

Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Psoriasis (PS) is a chronic skin inflammation. Up to 30% of the patients with PS develop psoriatic arthritis (PsA), a condition characterized by inflammatory arthritis that affects joints or entheses. Although there is mounting evidence for a critical role of interleukin-23 (IL-23) signaling in the pathogenesis of both PS and PsA, it remains unclear whether IL-23-induced skin inflammation drives joint disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65269-6DOI Listing

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

JAMA 2020 May;323(19):1945-1960

Keck School of Medicine, Department of Dermatology, University of Southern California Los Angeles.

Importance: Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.

Observations: Plaque psoriasis is the most common variant of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2020.4006DOI Listing

Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study.

Acta Radiol Open 2020 Apr 27;9(4):2058460120920797. Epub 2020 Apr 27.

Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Background: Psoriatic arthritis mutilans (PAM) is the most severe phenotype of psoriatic arthritis (PsA).

Purpose: To describe the radiological features in PAM and explore whether existing scoring systems for radiological damage in psoriatic arthritis are applicable for PAM.

Material And Methods: Radiographs were scored according to the modified Sharp-van der Heijde (mSvdH) and the Psoriatic Arthritis Ratingen Score (PARS) systems for PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2058460120920797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218277PMC

Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis.

Ann Rheum Dis 2020 May 18. Epub 2020 May 18.

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

Objectives: In treat to target (T2T), the patient is treated to reach and maintain specified and sequentially measured goals, such as remission or low disease activity. T2T in psoriatic arthritis (PsA) has demonstrated improved clinical and patient-reported outcomes and is recommended in European guidelines. However, most clinicians do not use T2T in PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217301DOI Listing

Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.

JAMA Neurol 2020 May 18. Epub 2020 May 18.

Department of Neurology, Mayo Clinic, Rochester, Minnesota.

Importance: Tumor necrosis factor (TNF) inhibitors are common therapies for certain autoimmune diseases, such as rheumatoid arthritis. An association between TNF inhibitor exposure and inflammatory central nervous system (CNS) events has been postulated but is poorly understood.

Objective: To evaluate whether TNF inhibitor exposure is associated with inflammatory demyelinating and nondemyelinating CNS events in patients with an indication for TNF inhibitor use and to describe the spectrum of those CNS events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2020.1162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235930PMC

Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study.

Clin Rheumatol 2020 May 16. Epub 2020 May 16.

Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, via Sergio Pansini 5, 80131, Naples, Italy.

Objective: To assess the effectiveness of steroid injection (local treatment, LT) into the digital flexor tendon sheath of dactylitis in psoriatic arthritis (PsA) patients as compared with systemic treatment (ST).

Methods: Forty-six PsA patients with a total of 73 dactylitic fingers were assessed in an observational, multicentre, prospective study by the Leeds Dactylitis Index basic (LDI-b) score and evaluated for local pain (visual analogue scale-VAS pain) and functional impairment (VAS-FI). Steroid injection was proposed to all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05142-zDOI Listing

From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention.

Curr Rheumatol Rep 2020 May 16;22(6):24. Epub 2020 May 16.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

Purpose Of Review: To describe the recent advances in the field towards the prevention and early recognition of Psoriatic Arthritis (PsA).

Recent Findings: Defining the preclinical phase of PsA remains challenging since up to 50% of subjects with psoriasis have subclinical imaging enthesopathy, but many of these do not progress to PsA. Nevertheless, there is evidence that subjects with subclinical imaging enthesopathy are at increased risk of developing PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-020-00891-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230038PMC

Increased prevalence of Lupus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study.

J Rheumatol 2020 May 15. Epub 2020 May 15.

From the The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Rheumatology Unit, Carmel Medical Center, Haifa, Israel; Chief Physician's Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel; Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel. Address correspondence to Dr. Devy Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal Street, Haifa 34362 Israel. Email:

Objective: To assess the prevalence of lupus (SLE) in a psoriatic arthritis (PsA) cohort and to compare it to the general population using the database of a large health care provider.

Methods: We analyzed the database of the PsA cohort (2002-2017) matched for age and sex with randomly selected controls for demographics, clinical and laboratory manifestations and dispensed medications. Statistical analysis used student's t-test, Chi square test, as appropriate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190940DOI Listing

The pattern of musculoskeletal complaints in patients with suspected psoriatic arthritis and their correlation with physical examination and ultrasound.

J Rheumatol 2020 May 15. Epub 2020 May 15.

Queen's University Medical School, Kingston, ON, Canada; Division of Rheumatology, Women's College Hospital, Toronto, ON, Canada; The Department of Physical Therapy, University of Toronto, Toronto, ON, Canada; Division of Dermatology, Women's College Hospital, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada. Samantha Sarabia was supported by a summer studentship award from the National Psoriasis Foundation. Lihi Eder is supported by a Young Investigator Award from the Arthritis Society. The early arthritis clinic was supported by unrestricted educational grants from UCB, Celgene, Novartis and Janssen. Address correspondence to Dr. Lihi Eder, Women's College Research Institute, Room 6326, Women's College Hospital, 76 Grenville Street, Toronto, Ontario, Canada, M5S 1B2. Email:

Objective: To describe the pattern of musculoskeletal symptoms and their correlation with clinical and sonographic findings among psoriasis patients with suspected psoriatic arthritis (PsA).

Methods: Patients with psoriasis and no prior diagnosis of PsA were referred for assessment of their musculoskeletal complaints. The study included the following steps: 1) assessment by an advanced practice physiotherapist; 2) targeted musculoskeletal ultrasound and 3) assessment by a rheumatologist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190857DOI Listing

The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?

Curr Opin Rheumatol 2020 May 13. Epub 2020 May 13.

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Purpose Of Review: To give an overview of the recently published trials relating to IL-23/IL-17 pathway in spondyloarthritis (SpA).

Recent Findings: Recent studies in psoriasis confirmed the efficacy of targeting the IL-23/IL-17 pathway, with emerging evidence from head-to-head studies suggesting functional hierarchy of these inhibitors. In psoriatic arthritis (PsA), recent studies have indicated the efficacy of inhibiting IL-23p19, in addition to IL-23p40 and IL-17A, albeit all with lower hurdle results than those seen in psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000719DOI Listing

MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis.

Curr Opin Rheumatol 2020 May 13. Epub 2020 May 13.

University College, Dublin, Ireland.

Purpose Of Review: To provide an overview of the heterogeneous human leucocyte antigen (HLA) associations of psoriatic arthritis, their relationship to particular clinical features of the disease, and how a hypothesis of binding specific peptides could provide a unifying basis for this heterogeneity.

Recent Findings: There have been substantive advances in understanding the role of HLA molecules in binding self-peptides that select our repertoire of T cells, the specific peptide-binding properties of these HLA allotypes, and their crystallographic structure. These advances provide a means to envision the significance of the heterogeneous psoriatic arthritis HLA associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000720DOI Listing

The management of enthesitis in clinical practice.

Curr Opin Rheumatol 2020 May 13. Epub 2020 May 13.

Division of Rheumatology, Women's College Hospital.

Purpose Of Review: Enthesitis is a hallmark feature of the spondyloarthropathies (SpA). This review provides an overview of recent insights on diagnosis and management of enthesitis.

Recent Findings: Recent studies support the use of imaging for diagnosis because of its higher sensitivity and specificity compared with clinical examination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000715DOI Listing

Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy.

Dermatol Res Pract 2020 2;2020:7209518. Epub 2020 May 2.

Postgraduate Program in Health Sciences, School of Medicine, Federal University of Uberlândia, Pará Av. 1720, Umuarama, Uberlândia, Minas Gerais, Brazil.

Psoriasis and psoriatic arthritis are chronic, relapsing, immune-based diseases. Psoriatic patients may have nail involvement in 50 to 80% of cases, and this may reach 85% in patients with joint disease, in spite of the fact that the relationship between psoriasis and onychomycosis is not well established. The aim of this study was to investigate the occurrence of onychomycosis in patients with nail disorders and diagnosis of psoriasis and psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/7209518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212309PMC

Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?

Curr Vasc Pharmacol 2020 May 14. Epub 2020 May 14.

Third Department of Cardiology, Athens University School of Medicine, Ippokrateio Hospital, Vas. Sofias 114, Athens 115 27. Greece.

In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, immunology and related fields. These reviews discuss the cardiovascular complications of the main systemic autoimmune rheumatic diseases (ARDs). For example, the underlying pathogenetic mechanisms, the role of cardiovascular imaging and recommendations for prevention and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1570161118666200514222236DOI Listing

Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.

RMD Open 2020 May;6(1)

UCSD, San Diego, California, USA.

Background: In psoriatic arthritis (PsA), both psoriasis and musculoskeletal manifestations may impair Health-Related Quality of Life (HRQoL). Our objective was to explore the impact of the various disease manifestations and disease consequences, including psychosocial factors, on HRQoL in PsA patients treated in the biologic treatment era.

Methods: Data collection in the 131 outpatient clinic PsA patients assessed included demographics, disease activity measures for both skin and musculoskeletal involvement and patient-reported outcome (PRO) measures, treatment and psychosocial burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2020-001223DOI Listing

Apremilast to treat oral ulcers in Behçet syndrome.

Authors:
H Yazici

Drugs Today (Barc) 2020 May;56(5):303-310

Professor of Medicine (Rheumatology), Academic Hospital, Istanbul, Turkey.

Apremilast, an oral small molecule, is a phosphodiesterase 4 (PDE-4) blocker. It has been shown to be efficacious in managing psoriasis (PS) and psoriatic arthritis (PSA). In two controlled studies, it was also effective in controlling oral ulcers of Behçet syndrome (Bsy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2020.56.5.3147942DOI Listing

Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study.

Eur J Hosp Pharm 2020 May 13. Epub 2020 May 13.

Pharmacy, University Hospital Complex of Vigo, VIGO, Spain.

Objectives: Medication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropathies: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Methods: Single institution, descriptive, retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2019-002133DOI Listing

Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients.

Antibodies (Basel) 2020 May 11;9(2). Epub 2020 May 11.

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, Viale Regina Elena 299, 00161 Rome, Italy.

Human cathelicidin LL37 is a cationic antimicrobial peptide active against bacteria and viruses and exerting immune modulatory functions. LL37 can be also a target of autoreactive B- and T-lymphocytes in autoimmune settings. Irreversible post-translational modifications, such as citrullination and carbamylation, mainly occurring at the level of cationic amino acids arginine and lysine, can affect the inflammatory properties and reduce antibacterial effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/antib9020014DOI Listing

Linguistic and Cultural Adaptation to Spanish of a Screening Tool for Use in Psoriatic Arthritis: The 4-item Psoriatic Arthritis Uncluttered Screening Evaluation.

Actas Dermosifiliogr 2020 May 11. Epub 2020 May 11.

Novartis pharmaceuticals Spain, Barcelona, España.

Background And Objective: The 4-item Psoriatic Arthritis Uncluttered Screening Evaluation (PURE-4) questionnaire is a useful tool for identifying patients with suspected psoriatic arthritis before referring them to a rheumatology department for confirmation. The original English version has good discriminant validity (sensitivity, 85.7%; specificity 83. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2020.03.004DOI Listing

Certolizumab for the Treatment of Psoriasis and Psoriatic Arthritis: A Real-World Multicentre Italian Study.

J Eur Acad Dermatol Venereol 2020 May 13. Epub 2020 May 13.

Department of Dermatology, University of Rome, Tor Vergata", Rome, Italy.

Background: Certolizumab, a pegylated tumour necrosis factor-α inhibitor, reduced disease activity in randomised trials of patients with psoriasis and psoriatic arthritis. Real-life data are missing.

Objective: To confirm the effectiveness and safety of certolizumab in patients with psoriasis and psoriatic arthritis in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16606DOI Listing

One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.

Expert Opin Biol Ther 2020 May 13:1-9. Epub 2020 May 13.

Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, Italy.

: Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking.: Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%).: Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2020.1761957DOI Listing

Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.

Int J Ophthalmol 2020 18;13(4):650-659. Epub 2020 Apr 18.

Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.

Aim: To conduct a systematic review and Meta-analysis to examine the association between uveitis and psoriatic disease, and to evaluate whether one condition predisposes individuals to the other.

Methods: We performed a comprehensive search of PubMed and EMBASE to identify cohort studies examining the association between uveitis and psoriatic disease [psoriasis and/or psoriatic arthritis (PsA)]. We used a random-effects model to calculate the pooled relative risks (RRs) adjusted for confounders, along with the 95% confidence intervals (CIs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18240/ijo.2020.04.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137715PMC

Methotrexate-Induced Pneumonitis in a Patient With Psoriatic Arthritis and Erythroderma.

Authors:
Ze-Hu Liu Hong Shen

J Clin Rheumatol 2020 May 9. Epub 2020 May 9.

From the Department of Dermatology, Affiliated Hangzhou Third Hospital, Anhui Medical University, Hangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001401DOI Listing

Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis.

J Eur Acad Dermatol Venereol 2020 May 12. Epub 2020 May 12.

Hospices Civils de Lyon, Université Claude Bernard Lyon I, Service de Dermatologie de l'Hôpital Edouard Herriot, Lyon, France.

We published in 2019 in the Journal of the European Academy of Dermatology and Venereology (JEADV) the first French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults . To evaluate the impact of these guidelines on the prescribing habits of French dermatologists, we conducted a survey before and after their official release. Dermatologists involved in the prescription of biologic agents in psoriasis were contacted through the mailing list of the French Society of Dermatology (FSD) and asked to analyze a clinical case describing an adult patient with moderate-to-severe cutaneous psoriasis with no comorbidities and without psoriatic arthritis (PsA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16601DOI Listing

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

RMD Open 2020 Feb;6(1)

Pfizer Inc, New York, New York, USA.

Objective: To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials.

Methods: Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2019-001042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999680PMC
February 2020

A new biomarker for psoriatic arthritis?

Br J Dermatol 2020 May 12. Epub 2020 May 12.

Conway Institute for Biomolecular Research, School of Medicine, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19141DOI Listing

Beyond skin deep: addressing comorbidities in psoriasis.

Med J Aust 2020 May 10. Epub 2020 May 10.

Skin Health Institute, Melbourne, VIC.

Psoriasis is a chronic inflammatory disease that is commonly encountered in primary care and is associated with significant morbidity that extends beyond the skin manifestations. Psoriasis is associated with an elevated risk of psoriatic arthritis, cardiovascular disease, obesity, insulin resistance, mental health disorders, certain types of malignancy, inflammatory bowel disease and other immune-related disorders, and hepatic and renal disease. Enhanced recognition of these comorbidities may lead to earlier diagnosis and potentially better overall health outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja2.50591DOI Listing

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Lancet 2020 05;395(10235):1496-1505

Novartis Pharmaceuticals, East Hanover, NJ, USA.

Background: Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endpoint of American College of Rheumatology (ACR) 20 response.

Methods: This parallel-group, double-blind, active-controlled, phase-3b, multicentre (168 sites in 26 countries) trial enrolled patients aged at least 18 years with active psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)30564-XDOI Listing

Psoriatic arthritis: still room for improvement.

Lancet 2020 05;395(10235):1463-1465

DANBIO Registry and Copenhagen Center for Arthritis Research, Rigshospitalet, DK-2600 Glostrup, Denmark; University of Copenhagen, Copenhagen, Denmark. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)30800-XDOI Listing

Features of the interconnection of traditional risk factors and il-10 with the activity of the inflammatory process and atherosclerosis development in patients with psoriatic arthritis.

Wiad Lek 2020 ;73(5):914-919

Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine.

Objective: The aim: To determine the features of atherosclerotic process, cardiovascular risk in patients with PsA.

Patients And Methods: Materials and methods: The study included 42 patients with PsA who did not have atherosclerotic CVD, diabetes, chronic kidney disease and other serious diseases, did not take statins, the comparingl group consisted of 20 patients with psoriasis (PS) and 20 practically healthy individuals who had no signs of rheumatic, infectious and other inflammatory diseases were screened.

Results: Results: It was revealed that in patients with PsA, the severity of the atherosclerotic process is more compared with patients with PS (the RF profiles were the same). Read More

View Article

Download full-text PDF

Source
January 2020

Probiotic Use and Psoriatic Arthritis Disease Activity.

ACR Open Rheumatol 2020 May 9. Epub 2020 May 9.

University of Nebraska Medical Center, Omaha, Nebraska.

Objective: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation. Spondyloarthropathies have subclinical gut inflammation associated with inflammatory disease that may benefit from probiotic use. We aimed to evaluate associations between probiotic use and patient-reported outcomes in patients with psoriatic arthritis (PsA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr2.11143DOI Listing

Peripheral spondyloarthritis: a neglected entity-state of the art.

RMD Open 2020 May;6(1)

Rheumatology, University Hospital Ghent, Ghent, Belgium.

Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or dactylitis predominate the clinical presentation. Although formal classification criteria for pSpA have been introduced in 2011, only a minority of epidemiological and clinical studies addressed this clinical entity as a separate disease. Moreover, research on outcome measures and treatment modalities in pSpA has been mainly focused on PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2019-001136DOI Listing

Cholestasis and disseminated histoplasmosis in a psoriatic patient on infliximab: case report and review of literature.

BMC Gastroenterol 2020 May 8;20(1):141. Epub 2020 May 8.

Division of Gastroenterology and Hepatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 646, Rochester, NY, 14642, USA.

Background: Histoplasma capsulatum is the most common endemic mycosis in the United States and frequently presents as an opportunistic infection in immunocompromised hosts. Though liver involvement is common in disseminated histoplasmosis, primary gastrointestinal histoplasmosis of the liver in absence of lung involvement is rare. Similarly, cholestatic granulomatous hepatitis in liver histoplasmosis is rarely seen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-01290-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206703PMC